Lacticaseicin 30 and Colistin as a Promising Antibiotic Formulation against Gram-Negative β-Lactamase-Producing Strains and Colistin-Resistant Strains.
Gram-negative clinical strains
RT-qPCR
beta-lactamase
colistin
lacticaseicin 30
synergistic activities
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
24 Dec 2021
24 Dec 2021
Historique:
received:
25
11
2021
revised:
19
12
2021
accepted:
21
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Antimicrobial resistance is a global health concern across the world and it is foreseen to swell if no actions are taken now. To help curbing this well announced crisis different strategies are announced, and these include the use of antimicrobial peptides (AMP), which are remarkable molecules known for their killing activities towards pathogenic bacteria. Bacteriocins are ribosomally synthesized AMP produced by almost all prokaryotic lineages. Bacteriocins, unlike antibiotics, offer a set of advantages in terms of cytotoxicity towards eukaryotic cells, their mode of action, cross-resistance and impact of microbiota content. Most known bacteriocins are produced by Gram-positive bacteria, and specifically by lactic acid bacteria (LAB). LAB-bacteriocins were steadily reported and characterized for their activity against genetically related Gram-positive bacteria, and seldom against Gram-negative bacteria. The aim of this study is to show that lacticaseicin 30, which is one of the bacteriocins produced by Lacticaseibacillus paracasei CNCM I-5369, is active against Gram-negative clinical strains (Salmonella enterica Enteritidis H10, S. enterica Typhimurium H97, Enterobacter cloacae H51, Escherichia coli H45, E. coli H51, E. coli H66, Klebsiella oxytoca H40, K. pneumoniae H71, K. variicola H77, K. pneumoniae H79, K. pneumoniae H79), whereas antibiotics failed. In addition, lacticaseicin 30 and colistin enabled synergistic interactions towards the aforementioned target Gram-negative clinical strains. Further, the combinations of lacticaseicin 30 and colistin prompted a drastic downregulation of mcr-1 and mcr-9 genes, which are associated with the colistin resistance phenotypes of these clinical strains. This report shows that lacticaseicin 30 is active against Gram-negative clinical strains carrying a rainbow of mcr genes, and the combination of these antimicrobials constitutes a promising therapeutic option that needs to be further exploited.
Identifiants
pubmed: 35052897
pii: antibiotics11010020
doi: 10.3390/antibiotics11010020
pmc: PMC8772908
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28320720
Front Microbiol. 2016 May 31;7:817
pubmed: 27303396
Nat Protoc. 2006;1(1):16-22
pubmed: 17406207
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:144-53
pubmed: 18154538
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31209009
Biotechnol Rep (Amst). 2021 May 25;30:e00632
pubmed: 34136365
Curr Issues Mol Biol. 2015;17:11-21
pubmed: 24821872
Vet World. 2019 Nov;12(11):1735-1746
pubmed: 32009752
Nat Protoc. 2008;3(2):163-75
pubmed: 18274517
Microbiol Rev. 1992 Sep;56(3):395-411
pubmed: 1406489
Front Microbiol. 2020 Feb 04;11:80
pubmed: 32117115
Res Microbiol. 2011 Feb-Mar;162(2):99-107
pubmed: 20868743
Membranes (Basel). 2020 Aug 08;10(8):
pubmed: 32784516
J Microbiol Methods. 2014 Aug;103:101-3
pubmed: 24912108
Food Microbiol. 2012 Oct;32(1):129-34
pubmed: 22850384
Int J Environ Res Public Health. 2020 Oct 26;17(21):
pubmed: 33114656
Probiotics Antimicrob Proteins. 2021 Aug;13(4):1213-1227
pubmed: 33481224
Benef Microbes. 2021 Jun 15;12(3):295-305
pubmed: 33789553
BMC Microbiol. 2019 Mar 18;19(1):60
pubmed: 30885126
Microb Pathog. 2019 Mar;128:171-177
pubmed: 30610901
Microbiol Mol Biol Rev. 2006 Jun;70(2):564-82
pubmed: 16760314
CSH Protoc. 2006 Jun 01;2006(1):
pubmed: 22485442
mBio. 2019 May 7;10(3):
pubmed: 31064835
Int J Antimicrob Agents. 2017 Jun;49(6):668-676
pubmed: 28457834
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32718964
Front Microbiol. 2016 Oct 26;7:1713
pubmed: 27833601
Int J Antimicrob Agents. 2018 Jun;51(6):822-828
pubmed: 29339296
Microorganisms. 2021 Feb 20;9(2):
pubmed: 33672663
Microb Ecol. 2017 Nov;74(4):1001-1008
pubmed: 28492988
Res Microbiol. 2011 May;162(4):386-92
pubmed: 21320595
Front Neurosci. 2017 Feb 14;11:73
pubmed: 28261050
Infect Drug Resist. 2018 Oct 10;11:1645-1658
pubmed: 30349322
Front Microbiol. 2017 Jun 29;8:1205
pubmed: 28706513
Sci Rep. 2018 May 8;8(1):7237
pubmed: 29740150
Antimicrob Agents Chemother. 2003 Aug;47(8):2385-92
pubmed: 12878494
J Antimicrob Chemother. 2006 Mar;57(3):573-6
pubmed: 16431863
Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents
pubmed: 11585791
Antimicrob Agents Chemother. 2013 Jun;57(6):2719-25
pubmed: 23571533
Expert Rev Clin Pharmacol. 2021 Sep;14(9):1113-1131
pubmed: 34015235
Food Microbiol. 2011 Oct;28(7):1339-44
pubmed: 21839383
Int J Mol Sci. 2020 Nov 17;21(22):
pubmed: 33212803
Microbiol Res. 2021 Nov;252:126864
pubmed: 34521050
J Antimicrob Chemother. 2020 Jul 1;75(7):1671-1680
pubmed: 32240295
Microorganisms. 2021 Oct 07;9(10):
pubmed: 34683428
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Appl Microbiol Biotechnol. 2016 Apr;100(7):2939-51
pubmed: 26860942
PLoS Pathog. 2016 Nov 28;12(11):e1005957
pubmed: 27893854
Infection. 2019 Jun;47(3):363-375
pubmed: 30840201
Annu Rev Biochem. 2002;71:635-700
pubmed: 12045108
Infect Genet Evol. 2009 May;9(3):322-7
pubmed: 18243815
Front Microbiol. 2014 Nov 26;5:643
pubmed: 25505462
J Appl Microbiol. 2007 Jun;102(6):1508-17
pubmed: 17578415
Biotechnol Rep (Amst). 2021 Mar 26;30:e00613
pubmed: 33996521
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Future Microbiol. 2019 Dec;14:1573-1587
pubmed: 32019322
Clin Microbiol Infect. 2016 May;22(5):416-22
pubmed: 26706614
P T. 2015 Apr;40(4):277-83
pubmed: 25859123
Drug Dev Res. 2017 Sep;78(6):283-291
pubmed: 28815721
Probiotics Antimicrob Proteins. 2021 Dec;13(6):1759-1765
pubmed: 34523112
PLoS Med. 2016 Nov 29;13(11):e1002184
pubmed: 27898664
J Antimicrob Chemother. 2020 Nov 1;75(11):3087-3095
pubmed: 32514524
Cell Mol Life Sci. 2013 Aug;70(16):2947-67
pubmed: 23109101
Curr Opin Biotechnol. 2018 Feb;49:23-28
pubmed: 28787641
Nat Rev Drug Discov. 2016 Jul 29;15(8):526
pubmed: 27469228
FEMS Microbiol Rev. 2021 Jan 8;45(1):
pubmed: 32876664
JAC Antimicrob Resist. 2021 Jul 16;3(3):dlab092
pubmed: 34286272
Saudi Med J. 2015 Feb;36(2):211-5
pubmed: 25719587
PLoS Pathog. 2014 Jul 31;10(7):e1004221
pubmed: 25079075
Nat Rev Microbiol. 2013 Feb;11(2):95-105
pubmed: 23268227
Food Microbiol. 2011 Aug;28(5):848-61
pubmed: 21569926
Appl Microbiol. 1971 May;21(5):943
pubmed: 4930039
Lancet Infect Dis. 2016 Feb;16(2):161-8
pubmed: 26603172
PLoS One. 2020 May 29;15(5):e0233284
pubmed: 32469943
Antimicrob Agents Chemother. 2006 Sep;50(9):3111-6
pubmed: 16940109
Curr Med Res Opin. 2015 Apr;31(4):707-21
pubmed: 25697677
Int J Antimicrob Agents. 2017 Jan;49(1):1-11
pubmed: 27773497